Eli Lilly

Green Circle Life Expands Availability of Healthy Weight for Life Program for the SmartFHR™ Platform

Retrieved on: 
Tuesday, April 16, 2024
Technology, Professional Services, Health, Pharmaceutical, Health Technology, Health Insurance, Data Analytics, Software, Fitness & Nutrition, Human Resources, Telemedicine, Virtual Medicine, Snack, ROI, Pharmacy, NCQA, AutoZone, HR, Eli Lilly, Insurance, Compensation, Partnership, Weight loss, Doctor of Philosophy, Quality assurance, Pharmacotherapy, Prescription, Obesity, Exercise, Life, Novo Nordisk, Diet, GCL, Workforce, National Committee, Quality of life

HWFL is an employer-offered weight management program designed to work with individuals to set realistic goals, attain and maintain their desired weight through lifestyle changes.

Key Points: 
  • HWFL is an employer-offered weight management program designed to work with individuals to set realistic goals, attain and maintain their desired weight through lifestyle changes.
  • The program, which provides private, personalized coaching, encourages users to engage in physical activities, nutritional adjustments and monitor weight outcomes.
  • Dinesh Sheth, founder and CEO of Green Circle Life, emphasized, “Health and wellness are at the forefront of HR challenges, and obesity is a national epidemic.
  • Healthy weight is not a 'one and done' 'one size fits all' proposition but rather a constantly evolving journey.

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

Retrieved on: 
Wednesday, April 10, 2024
Biotechnology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Surgery, Science, Disorder, T2D, Connective tissue, Bariatric surgery, Eli Lilly, Human, Weight, Tirzepatide, Metabolism, Obesity, Type 2 diabetes, Patient, Society, Magnetic resonance imaging, MRI, Multimedia, ASMBS, Medical imaging

For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.

Key Points: 
  • For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
  • The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population.
  • The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
  • The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.

Indiana #1 Midwest State in Chief Executive Magazine's 2024 CEO Survey of Best and Worst States for Business

Retrieved on: 
Wednesday, April 24, 2024
Best, City, Conco, Eli Lilly, Business, Nation, Hoosier, Environment, EV, GM, Economic development, Workforce, Quality of life, Growth, Samsung, Management

NASHVILLE, Tenn., April 24, 2024 /PRNewswire/ -- CEOs surveyed for Chief Executive magazine's annual list of the Best and Worst States for Business once again ranked Indiana as the top-ranked Midwestern state and the sixth-best state for business overall, maintaining its elite position on the list from last year.

Key Points: 
  • NASHVILLE, Tenn., April 24, 2024 /PRNewswire/ -- CEOs surveyed for Chief Executive magazine's annual list of the Best and Worst States for Business once again ranked Indiana as the top-ranked Midwestern state and the sixth-best state for business overall, maintaining its elite position on the list from last year.
  • The rankings, released in the Spring issue of Chief Executive, reflect Indiana's ongoing efforts to create a welcoming environment for businesses of all sizes and industries.
  • "This ranking is a testament to Indiana's commitment to fostering a business-friendly environment that encourages growth and innovation," said Chris Chalk, Publisher, Chief Executive magazine.
  • "From its skilled workforce to its strategic location and pro-business policies, Indiana offers everything businesses need to succeed."

Solving unmet needs in GLP1 cardiometabolic clinical trials: novel approaches to digital data capture & patient retention (Upcoming Xtalks webinar hosted by Clinical ink)

Retrieved on: 
Monday, April 22, 2024
FDA, GLP1, Health, Blood, Eli Lilly, Diabetes, CGM, Web conferencing, Data science, MD, Doctor of Philosophy, American Opportunity Tax Credit, Entrepreneurship, Obesity, Environment, NASH, Disease, Senior, Hypoglycemia, Actigraphy, GCP, BGM, Biomarker, Clinical trial, MASH, BST, Medical imaging

TORONTO, April 22, 2024 /PRNewswire-PRWeb/ -- New treatment options, including glucagon-like peptide-1 (GLP1) agents, are under investigation for treating cardiometabolic diseases such as diabetes, weight management/obesity and metabolic dysfunction-associated steatohepatitis (MASH)/non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Panelists will discuss the complexity of digital systems required to continuously monitor symptoms, signs, and digital biomarkers in this diverse patient population.
  • Another key topic with cardiometabolic clinical trials is compliance and dropouts.
  • Hypoglycemia needs to trigger an e-diary and all data should be available in real time to sponsors and clinical research organizations.
  • To capture all these data in a single system Clinical ink has developed GlucoseReadyTM, an integrated GCP compliant digital platform.

AskBio Names Mansuo Shannon Chief Scientific Officer

Retrieved on: 
Tuesday, April 9, 2024
Eli Lilly, Alzheimer's disease, Gene editing, Princeton University, MIT, Research, Bayer, Chugai Pharmaceutical Co., Doctor of Philosophy, Samulski, Therapy, Eli Lilly and Company, CSO, Molecular biology, Management

Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Key Points: 
  • Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
    Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
    Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that on April 8, 2024, Mansuo Shannon, PhD, was named the company’s next Chief Scientific Officer (CSO).
  • Shannon joins AskBio from Prevail Therapeutics, where she also served as CSO.
  • Reporting to Gustavo Pesquin, Chief Executive Officer (CEO), Shannon will be a member of AskBio’s Executive Leadership Team and head its R&D organization.
  • As part of her role as CSO at AskBio, Shannon will develop and implement the company’s future R&D strategy.

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Retrieved on: 
Wednesday, March 27, 2024
Eli Lilly, Disease, Half-life, Partnership, Patient, Sale, Acquisition, Inflammation, Therapy, OrbiMed, Hidradenitis suppurativa, Probability, Autoimmune disease

Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027

Key Points: 
  • Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027
    Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.
  • The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million.
  • After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million.
  • The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions.

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Retrieved on: 
Wednesday, March 27, 2024
Transforming growth factor beta, Eli Lilly, Atrophy, DVM, Obesity, Drug discovery, Exercise, Partnership, Patient, SAN, EDT, Learning, Entrepreneurship, IND, Antibody, Drug development, PIPE, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.

Key Points: 
  • Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors.
  • The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
  • The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise.
  • iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

AMERICAN SKIN ASSOCIATION SPRING GALA CELEBRATES OUTSTANDING HONOREES

Retrieved on: 
Friday, April 5, 2024
Eli Lilly, Organization, Master of ceremonies, Psoriasis, Vitiligo, Atopic dermatitis, Skin cancer, NBC, Patient, Research, Pioneer, Hope, Doctor of Philosophy, MD, Student, Inauguration, SPOTS, ASA, Skin, Melanoma, Eli Lilly and Company, Plaza Hotel, Physician, Pharmaceutical industry

NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala. They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health. The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.

Key Points: 
  • Gala honors Pioneer in Dermatology, Emma Guttman-Yassky, MD, PhD and Global Pharmaceutical Leader Eli Lilly and Company
    NEW YORK, April 5, 2024 /PRNewswire/ -- On Thursday evening, at The Plaza Hotel, American Skin Association (ASA) held their Spring Gala.
  • They presented awards to two outstanding honorees and celebrated another successful year of funding research and educating youth on skin health.
  • The gala was attended by ASA's loyal supporters and donors, including philanthropists, business leaders, and renowned physicians from the field of dermatology.
  • Recipients, who work on breakthrough efforts to prevent, detect, and treat skin cancer and other skin diseases, have gone on to become top researchers in dermatology.